Substituted azepinone dual inhibitors of angiotensin converting enzyme
申请人:E. R. Squibb & Sons, Inc.
公开号:US05552397A1
公开(公告)日:1996-09-03
Compounds of the formula ##STR1## are disclosed as possessing inhibitory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and thus being useful as cardiovascular agents. Processes for preparing these compounds are also disclosed.
The present invention relates to a compound of Formula (I):
or
a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.
Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed as possessing inhibotory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and thus being useful as cardiovascular agents.
Dual action inhibitors containing a pyridazinodiazepine or
申请人:E. R. Squibb & Sons, Inc.
公开号:US05723602A1
公开(公告)日:1998-03-03
Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and are thus useful as cardiovascular agents.
Azepinones useful as intermediates in the preparation of inhibitors of
申请人:E. R. Squibb & Sons, Inc.
公开号:US05856477A1
公开(公告)日:1999-01-05
The azepine intermediates of the formula ##STR1## wherein R.sub.6 and R.sub.7 are other than hydrogen are disclosed. These intermediates can be reacted with acylmercaptocarboxylic acids of the formula ##STR2## to give the pharmaceutically active products.